Additional file 2: of TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines

Figure S1Genomic copy number levels of CDKN2A in primary MM.Figure S2Bioinformatic analysis of TrkA mRNA expression and copy number in public database of MM cell lines and tumor samples.Figure S3 Expression of TrkA in MM cell lines.Figure S4Dose-response activation of AKT and MAPK following stimulation of NGF-TrkA signaling in MM cell lines.Figure S5Morphological and quantitative analysis of MM cells in response to NGF-TrkA signaling.Figure S6 Cell proliferation and apoptosis analysis of MM cells in the absence of active NGF-TrkA signaling following MAPK and AKT pathway inhibition.Figure S7Proliferation of MM cells in the absence of active NGF-TrkA signaling following MAPK and AKT pathway inhibition.Figure S8 Analysis of MAPK downstream target expression following NGF-TrkA signaling in MM cells.Figure S9 Analysis of MAPK activation and p21cip1 expression in MM cells in the absence of NGF-TrkA signaling following inhibition of MAPK pathway in MM cells.Figure S10 Morphological analysis of MM cells in the absence of NGF-TrkA signaling activation and following inhibition of MAPK pathway.